<code id='D2FB631E6A'></code><style id='D2FB631E6A'></style>
    • <acronym id='D2FB631E6A'></acronym>
      <center id='D2FB631E6A'><center id='D2FB631E6A'><tfoot id='D2FB631E6A'></tfoot></center><abbr id='D2FB631E6A'><dir id='D2FB631E6A'><tfoot id='D2FB631E6A'></tfoot><noframes id='D2FB631E6A'>

    • <optgroup id='D2FB631E6A'><strike id='D2FB631E6A'><sup id='D2FB631E6A'></sup></strike><code id='D2FB631E6A'></code></optgroup>
        1. <b id='D2FB631E6A'><label id='D2FB631E6A'><select id='D2FB631E6A'><dt id='D2FB631E6A'><span id='D2FB631E6A'></span></dt></select></label></b><u id='D2FB631E6A'></u>
          <i id='D2FB631E6A'><strike id='D2FB631E6A'><tt id='D2FB631E6A'><pre id='D2FB631E6A'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:129
          gantenerumab Alzheimer's disease Roche
          Sebastien Bozon/AFP via Getty Images

          LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading. 

          The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled. 

          advertisement

          The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          H5N1 bird flu virus started spreading in cows in Texas in December
          H5N1 bird flu virus started spreading in cows in Texas in December

          ColorizedmicroscopicimageofH5N1birdfluvirusparticles(inyellow).NIAIDAsagriculturalauthoritiesandepid

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          The new HIV moral panic

          Gilead'sPrEPpillTruvadaJustinSullivan/GettyImagesInMay,justbeforePrideMonth,theCentersforDiseaseCont